Physician

Karen L Lorusso, MD

According to 2025 Medicare claims, Karen Lorusso, MD (NPI: 1578562393) practices medical oncology in the Santa Fe, NM market, with the plurality of this provider's patient population coming from Santa Fe, NM. This provider's primary affiliated billing organization is NEXUS HEALTH (NPI: 1801516489; TIN: 87-3699084) and primary practice location at 87507-9998.

Lorusso's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 535 traditional Medicare patients, billed 62,696 HCPCS/CPT codes, and received $1,904,227 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 996 prescription claims across 193 beneficiaries totaling $2,570,300 in drug costs, led by Revlimid (Lenalidomide). DME data shows 20 claims. Open Payments data shows 67 records totaling $1,326. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $131,364 to $1,904,227. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $715,667 to $2,570,300. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,293 and ending at $4,068.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	414	4,715	$131,364
2016	467	1,604	$104,469
2017	488	1,819	$160,692
2018	486	1,768	$162,119
2019	405	1,611	$153,188
2020	415	1,590	$162,454
2021	450	1,496	$156,410
2022	433	1,118	$101,083
2023	442	52,872	$1,355,479
2024	535	62,696	$1,904,227

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	198	905	$715,667
2016	209	970	$1,084,731
2017	188	816	$1,046,214
2018	202	920	$1,398,759
2019	205	1,035	$1,845,445
2020	196	1,134	$1,799,149
2021	230	1,230	$1,834,800
2022	236	1,159	$2,495,595
2023	200	958	$1,736,984
2024	193	996	$2,570,300

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$2,012
2016	N/R	26	$10,918
2017	N/R	122	$24,374
2018	N/R	62	$8,009
2019	11	89	$8,167
2020	N/R	110	$7,198
2021	N/R	38	$2,991
2022	N/R	77	$4,933
2023	N/R	57	$4,414
2024	N/R	20	$1,382

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	94	184	$135
96413	Administration of chemotherapy into vein, 1 hour or less	73	162	$94
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	211	421	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	231	343	$61
96375	Injection of additional new drug or substance into vein	56	284	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	39	1,092	$697,329
Pomalyst	Pomalidomide	20	560	$443,719
Jakafi	Ruxolitinib Phosphate	23	690	$346,170
Imbruvica	Ibrutinib	13	364	$200,253
Calquence	Acalabrutinib Maleate	14	420	$172,277

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	20	$1,382

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	67	$1,326	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Karen L. Lorusso, MD?

Tedicare shows public-source Medicare data for Karen L. Lorusso, MD (NPI 1578562393), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Karen L. Lorusso, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Karen L. Lorusso, MD?

Karen L. Lorusso, MD is linked to NEXUS HEALTH (billing NPI 1801516489) in the available physician profile data.

Does Karen L. Lorusso, MD have Open Payments data?

Karen L. Lorusso, MD has 67 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.